Alergoprofil

You can set an example too ? how to effectively and safely use budesonide in nebulization?

Andrzej Emeryk — Sun, 15 Jun 2025 00:00:00 +0200

The basic pharmacokinetic and pharmacodynamic properties of budesonide in the form of a nebulization suspension are discussed. This drug is used in inhalation therapy of numerous inflammatory and obstructive respiratory diseases in newborns, infants, older children and adults. It is most often used in acute laryngitis (various forms) and asthma (exacerbations, chronic therapy). The most important principles of correct nebulization of budesonide using different nebulizers are given. Attention was drawn to possible errors during nebulization.

The efficacy of ebastine in the treatment of urticaria

Monika Sikorska, Roman J. Nowicki — Wed, 28 May 2025 00:00:00 +0200

Urticaria is a common dermatological condition characterized by the occurrence of urticarial wheals and/or angioedema. It can be classified as acute (lasting up to 6 weeks) or chronic (lasting more than 6 weeks), which may be spontaneous or induced by various stimuli. The pathophysiology of urticaria is mainly based on the release of histamine from mast cells and basophils, leading to clinical symptoms. Ebastine is a second-generation antihistamine, a selective H1 receptor antagonist that exhibits multidirectional anti-inflammatory properties. In addition to blocking histamine receptors, it inhibits the release of prostaglandins, leukotrienes, and proinflammatory cytokines. After oral administration, it is rapidly metabolized to carebastine, an active metabolite with a long half-life, allowing for once-daily dosing. The efficacy of ebastine has been confirmed in various forms of urticaria. In chronic spontaneous urticaria, which accounts for 80?90% of all chronic urticaria cases, ebastine at a dose of 10 mg significantly reduces itching and the number and size of wheals. Clinical efficacy is maintained long-term without the development of tachyphylaxis. In patients with insufficient response to standard doses, increasing the dose to 20 mg or 40 mg improves symptom control. The drug also shows efficacy in dermographic urticaria, cold urticaria, and acute urticaria. It has a favorable safety profile, minimal impact on the central nervous system, and no cardiotoxic effects even at increased doses. The most common side effects are headache, drowsiness, and dry mouth. A practical advantage of ebastine is its availability in the form of fast-dissolving tablets, which are preferred by patients.

Advantages and benefits of using the combination of mometasone furoate and olopatadine in the treatment of allergic rhinitis

Adam J. Sybilski, Weronika Balas — Tue, 30 Sep 2025 00:00:00 +0200

Allergic rhinitis (AR) is one of the most common chronic diseases worldwide. Management of AR is based on a strategy that includes allergen avoidance, pharmacotherapy, and allergen immunotherapy. Intranasal glucocorticosteroids (nGCS) and oral or intranasal antihistamines (LH1) are key components of treatment. However, despite their effectiveness, many patients still experience inadequate symptom control or expect faster symptom relief. A key advantage of the combination of mometasone furoate (nGCS) and olopatadine hydrochloride (an intranasal antihistamine) is their complementary and synergistic effects on the complex pathophysiology of AR.

Numerous clinical studies confirm the superior efficacy of the intranasal combination of olopatadine and mometasone (Olo-Mom) over monotherapy and placebo in the treatment of both seasonal (SAR) and perennial (PAR) allergic rhinitis. The combination of LH1+nGCS may also be associated with improved quality of life and ocular symptoms in children with ARS.

Key advantages and benefits of the Olo-Mom combination include: synergistic action, higher clinical efficacy, rapid onset, high patient satisfaction, improved adherence, and a favorable safety profile.

The supportive role of intranasal mometasone furoate in controlling bronchial asthma

Bartosz Pałdyna — Wed, 23 Apr 2025 00:00:00 +0200

Bronchial asthma and allergic rhinitis are chronic inflammatory diseases of the respiratory system with a common immunological ground based on the predominance of the Th2 response. The presence of allergic rhinitis significantly increases the risk of developing bronchial asthma, and the coexistence of these two conditions adversely affects symptom control, exacerbation frequency, and quality of life of patients. Contemporary pathophysiological concepts assume the existence of a close functional and immunological relationship between the upper and lower respiratory tract. Chronic inflammation in the nose can initiate and sustain an inflammatory response in the bronchi, thereby worsening the course of allergic rhinitis.

Mometasone furoate, a new-generation intranasal glucocorticosteroid, has a strong anti-inflammatory effect with minimal systemic bioavailability. It inhibits key inflammatory cytokines (IL-4, IL-5, IL-13), reduces eosinophil infiltration, and improves nasal mucosal function. Numerous studies have shown that its use in patients with allergic rhinitis and concomitant bronchial asthma improves respiratory parameters, reduces asthma symptoms, decreases the need for as-needed medication, and improves quality of life.

The article reviews current data on the supportive role of mometasone furoate in the treatment of bronchial asthma in the context of integrated care. The importance of early intervention, especially in children, is also emphasized in the context of the possible impact of chronic nasal obstruction on the morphological development of the facial skeleton.

Use of bilastine in clinical practice ? case reports

Edyta Jura-Szołtys — Mon, 30 Jun 2025 00:00:00 +0200

Allergic diseases are one of the largest groups of civilization disorders in the world. The main disease entities are allergic rhinitis and urticaria. Effective therapy for these conditions is based on second-generation antihistamines that selectively inhibit the H₁ receptor. One of the most modern products of this group is bilastine, which is characterized by high efficacy and a very high safety profile. The publication presents cases from everyday clinical practice in which bilastine was used in patients with allergic rhinitis and urticaria.